CD274 and non-small cell lung carcinoma: Recently, the phase III PACIFIC trial (NCT02125461) evaluated consolidation therapy with anti-programmed cell death ligand-1 (anti-PD-L1) in patients with unresectable stage III NSCLC who did not experience disease progression after chemoradiotherapy (CRT).